Prescribing should be consistent with the need to minimize the risk of tardive dyskinesia, seizures, and orthostatic hypotension. A rare condition referred to as neuroleptic malignant syndrome (NMS) has been reported with this class of medications, including SEROQUEL.
There have been reports of diabetes mellitus and hyperglycemia related adverse events associated with the use of atypical antipsychotics, including SEROQUEL. Click here to read AstraZeneca’s letter to Health Care Providers.
The most commonly observed adverse events associated with the use of SEROQUEL in clinical trials for either schizophrenia or as monotherapy in bipolar mania were somnolence (18%), dizziness (11%), dry mouth (9%), constipation (8%), SGPT increase (5%), dyspepsia (5%), and weight gain (5%). The most commonly observed adverse events associated with the use of SEROQUEL in clinical trials as adjunct therapy with lithium or divalproex in bipolar mania were somnolence (34%), dry mouth (19%), constipation (10%), asthenia (10%), abdominal pain (7%), postural hypotension (7%), pharyngitis (6%), and weight gain (6%).
In the elderly and in patients with hepatic impairment, consideration should be given to a lower starting dose, a slower rate of dose titration, careful monitoring during the initial dosing period, and a lower target dose.
SEROQUEL® Prescribing Information. AstraZeneca Pharmaceuticals LP, Wilmington, Delaware.